Indapamide

General Toxicity Notes
Natriuretic drugs may cause extracellular fluid volume depletion.
Excreted Unchanged %
7
Half-Life (Normalesrd) Hours
14-18/Unchanged
Plasma Protein Binding %
76-79
Volume Of Distribution L/Kg
0.3-1.3
Dose For Normal Renal Function
1.25 mg q24h
Second Dose
Second Dose: 1.25-5 mg q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Ineffective [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Ineffective, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Ineffective, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable, [D]
References
Chaffman M, Heel RC, Brogden RN, Speight TM, Avery GS. Indapamide. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1984; 28: 189-235. [PMID: 6489195] / Madkour H, Ali K, Nosrati S, Massry SG. Efficacious response with low-dose indapamide therapy in the treatment of type II diabetic patients with normal renal function or moderate renal insufficiency and moderate hypertension. Am J Nephrol. 2002; 22: 2-5. [PMID: 11919395] / Urien S, Morin D, d&#146; Athis P, Coulomb B, Tillement JP. Serum binding of indapamide in health and disease: primary role of alpha 1-acid glycoprotein. J Clin Pharmacol. 1988; 28: 458-62. [PMID: 3392244]
Toxicity Notes
Usually ineffective when GFR <30 mL/min. Ineffective in ESRD. Effective in treatment of moderate hypertension in patients with moderate renal insufficiency.